In the primary analysis for Harmoni-2, ivonescimab monotherapy demonstrated a statistically significant improvement in the trial’s primary endpoint, progression-free survival (PFS), achieving a hazard ...

On Friday, the Minnesota Department of Agriculture issued an alert for Gerber Soothe 'N' Chew Teething Sticks. The alert ...

While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, ...